Table 1.
Common treatments for patients with SSc after 1 year of follow-up from the diagnosis index date
| Type of drug | Patients, n (%) N = 6852a |
|---|---|
| Antibiotics | 4228 (61.7) |
| Opioids | 3465 (50.6) |
| Glucocorticoids | 3186 (46.5) |
| PPIs | 2425 (35.4) |
| NSAIDs | 1770 (25.8) |
| IMTs except biologicsb | 1551 (22.6) |
| Hydroxychloroquine | 1148 (16.8) |
| ACE inhibitors | 922 (13.5) |
| Calcium antagonists | 881 (12.9) |
| Prokinetic drugs | 470 (6.9) |
| ERA | 119 (1.7) |
| Biologicsc | 111 (1.6) |
| Prostacyclin | 20 (0.3) |
All data are number (%) of patients receiving drug
ACE angiotensin-converting enzyme, ERA endothelin receptor agonist, IMT immunomodulating therapy, NSAIDs nonsteroidal anti-inflammatory drugs, PPIs proton pump inhibitors
aPatients with valid treatments of interest (defined as at least 1 day’s supply)
bIncluded azathioprine, chloroquine phosphate, cyclophosphamide, cyclosporine, leflunomide, mycophenolate mofetil, methotrexate, penicillamine, quinacrine hydrochloride, and sulfasalazine
cIncluded the biologics abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, and the targeted synthetic disease-modifying antirheumatic drug (DMARD) tofacitinib